GlassScriptPhysician profile
Mackenzie E Coleman
NPI 1790406270
$2,369.87
in general payments reported to CMS, 2019-2025
21 companies · $1,001 in 2025
The $1,001 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $255 · 2024: $1,114 · 2025: $1,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,369.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $664.11 | 2024-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $290.41 | 2023-2025 | |
| Novo Nordisk INC | $279.24 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $247.59 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $139.06 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $97.29 | 2024-2025 | Spravato |
| Amgen INC. | $95.65 | 2024-2025 | Krystexxa, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $82.71 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $81.68 | 2023 | Quviviq |
| Organon LLC | $77.52 | 2024 | |
| Exact Sciences Corporation | $69.81 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Astellas Pharma US INC | $50.32 | 2024 | Veozah |
| Mayne Pharma Commercial LLC | $29.63 | 2024 | |
| Edwards Lifesciences Corporation | $24.68 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Collegium Pharmaceutical, INC. | $22.99 | 2025 | Jornay Pm |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $21.50 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $21.48 | 2025 | Austedo Xr |
| Novartis Pharmaceuticals Corporation | $21.34 | 2024 | |
| Merck Sharp & Dohme LLC | $19.34 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Paratek Pharmaceuticals, INC. | $18.59 | 2025 | Nuzyra |
| Xeris Pharmaceuticals, INC. | $14.93 | 2024 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mackenzie Coleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.